SCHEMBL6168734

SCHEMBL6168734

O=C(O)c1ccc2c(c1)nc(Cc1ccccc1)n2Cc1ccccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 6/20 0.59
JAK2 O60674 1/20 0.55
JAK1 P23458 1/20 0.55
TYK2 P29597 1/20 0.55
JAK3 P52333 1/20 0.55
TP53 P04637 1/20 0.53
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
LMNA P02545 1/20 0.51
PTGES O14684 1/20 0.51
ALOX5 P09917 1/20 0.51
LTC4S Q16873 1/20 0.51
PPARG P37231 1/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6170162 0.91 ALOX5AP (0.54) ALOX5APJAK2JAK1TYK2JAK3
SCHEMBL6168520 0.90 JAK2 (0.53) ALOX5APJAK2JAK1TYK2JAK3
SCHEMBL6171536 0.87 CNR2 (0.56) ALOX5APJAK2JAK1TYK2JAK3
SCHEMBL6169342 0.86 AGTR1 (0.62) ALOX5APTP53PTGESPPARG
SCHEMBL1160318 0.85 TP53 (0.51) ALOX5APJAK2JAK1TYK2JAK3
SCHEMBL6170907 0.84 AGTR1 (0.66) ALOX5APLMNASMN1; SMN2NPSR1
SCHEMBL4570712 0.83 PPARG (0.68) ALOX5APTP53PTGESALOX5LTC4S
SCHEMBL6169301 0.82 TP53 (0.52) ALOX5APTP53LMNAPPARGMEN1
SCHEMBL9531834 0.81 ALOX5AP (0.50) ALOX5APJAK2JAK1TYK2JAK3
SCHEMBL7669594 0.79 TP53 (0.54) ALOX5APTP53PPARGMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 US disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 US disclosed
US-6211177-B1 SIDE EFFECT REDUCTION CELL PATHWAYS, INC. 2001-04-03 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 ALOX5AP 3905/4885JAK2 1807/4885JAK1 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.